MedTrace Logo

Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

NCT02344511 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-09-23

No results posted yet for this study

Summary

Dalbavancin for Pediatric Osteomyelitis

Conditions

  • Osteomyelitis

Interventions

DRUG

Dalbavancin

Drug

DRUG

cefazolin, nafcillin, oxacillin or vancomycin

Standard of Care

Sponsors & Collaborators

  • Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)

    lead INDUSTRY

Principal Investigators

  • Alena Jamdourek, MD · Durata Therapeutics Inc., an affiliate of Allergan plc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-10-31
Completion
2019-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02344511 on ClinicalTrials.gov